World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
77
Citations
26711
World Ranking
18310
National Ranking
1664

Gordon C Jayson publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Gordon C Jayson sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 446 publications — 48th percentile

48% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Gordon C Jayson D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Gordon C Jayson sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 77 D-Index — 10th percentile

10% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

Gordon C Jayson is affiliated with the University of Manchester in the United Kingdom. Their research focuses primarily on medicine, with a substantial output in reproductive medicine, oncology, genetics, molecular biology, and surgery. Their work addresses clinical and molecular aspects within these domains, emphasizing ovarian cancer and related therapeutic approaches.

The scientist's research covers a range of main topics, including ovarian cancer diagnosis and treatment, PARP inhibition in cancer therapy, BRCA gene mutations in cancer, intraperitoneal and appendiceal malignancies, CRISPR and genetic engineering, renal cell carcinoma treatment, and endometriosis research and treatment.

Jayson has contributed to several scientific publications, with frequent appearances in notable venues. These include:

  • Annals of Oncology
  • International Journal of Gynecological Cancer
  • British Journal of Cancer
  • Cancers
  • The Cambridge Structural Database

Their recent published papers demonstrate a focus on ovarian cancer and its therapeutic management. Selected recent works are:

  • "A living biobank of ovarian cancer ex vivo models reveals profound mitotic heterogeneity," 2020, Nature Communications
  • "First-Line Management of Advanced High-Grade Serous Ovarian Cancer," 2020, Current Oncology Reports
  • "Objective responses to first-line neoadjuvant carboplatin-paclitaxel regimens for ovarian, fallopian tube, or primary peritoneal carcinoma (ICON8): post-hoc exploratory analysis of a randomised, phase 3 trial," 2020, The Lancet Oncology
  • "Safety and efficacy of the tumor-selective adenovirus enadenotucirev with or without paclitaxel in platinum-resistant ovarian cancer: a phase 1 clinical trial," 2021, Journal for ImmunoTherapy of Cancer
  • "Mainstreaming germline BRCA1/2 testing in non-mucinous epithelial ovarian cancer in the North West of England," 2020, European Journal of Human Genetics

Frequent collaborators in Jayson's research include Andrew R. Clamp, Robert D. Morgan, Jurjees Hasan, D. Gareth Evans, and Zena Salih. The volume of coauthored works with these colleagues ranges from 17 to 35 publications, highlighting ongoing collaborative efforts within the field.

Best Publications

  • Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial.

    MK Parmar;JA Ledermann;N Colombo;Bois A Du

  • Primary chemotherapy versus primary surgery for newly diagnosed advanced ovarian cancer (CHORUS): an open-label, randomised, controlled, non-inferiority trial

    Sean Kehoe;Jane Hook;Matthew Nankivell;Gordon C Jayson

  • Imaging biomarker roadmap for cancer studies.

    James P.B. O'Connor;Eric O. Aboagye;Judith E. Adams;Hugo J.W.L. Aerts;Hugo J.W.L. Aerts

  • Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial.

    Amit M. Oza;Adrian D. Cook;Jacobus Pfisterer;Andrew Embleton

  • Antiangiogenic therapy in oncology: current status and future directions.

    Gordon C Jayson;Robert Kerbel;Lee M Ellis;Adrian L Harris

  • Experimentally-derived functional form for a population-averaged high-temporal-resolution arterial input function for dynamic contrast-enhanced MRI.

    Geoffrey James Parker;Caleb Roberts;Andrew Macdonald;Giovanni A Buonaccorsi

  • Phase III Randomized Trial of Docetaxel–Carboplatin Versus Paclitaxel–Carboplatin as First-line Chemotherapy for Ovarian Carcinoma

    Paul Vasey;Gordon C Jayson;Alan Gordon;Hani Gabra

  • Early versus delayed treatment of relapsed ovarian cancer (MRC OV05/EORTC 55955): a randomised trial.

    Gordon J.S. Rustin;Maria E.L. Van Der Burg;Clare L. Griffin;David Guthrie

  • DCE-MRI biomarkers in the clinical evaluation of antiangiogenic and vascular disrupting agents

    James P B O'Connor;Alan Jackson;Geoff J M Parker;Gordon C Jayson

  • The assessment of antiangiogenic and antivascular therapies in early-stage clinical trials using magnetic resonance imaging: issues and recommendations

    Martin O Leach;K Brindle;J Evelhoch;John R Griffiths

  • Intra-tumoural microvessel density in human solid tumours.

    Jurjees Hasan;Richard J Byers;Gordon C Jayson

  • Dynamic contrast-enhanced MRI in clinical trials of antivascular therapies

    James P. B. O'Connor;Alan Jackson;Geoff J. M. Parker;Caleb Roberts

  • Imaging tumor vascular heterogeneity and angiogenesis using dynamic contrast-enhanced magnetic resonance imaging.

    Alan Jackson;James P.B. O'Connor;Geoff J.M. Parker;Gordon C. Jayson

  • Molecular Imaging and Biological Evaluation of HuMV833 Anti-VEGF Antibody: Implications for Trial Design of Antiangiogenic Antibodies

    Gordon C Jayson;Jamal Zweit;Alan Jackson;Clive Mulatero

  • Prospective evaluation of oral mucositis in patients receiving myeloablative conditioning regimens and haemopoietic progenitor rescue.

    A.M. Wardley;G.C. Jayson;R. Swindell;G.R. Morgenstern

  • Biomarkers of angiogenesis and their role in the development of VEGF inhibitors

    N Murukesh;Caroline Dive;Gordon C Jayson

  • Cediranib in patients with relapsed platinum-sensitive ovarian cancer (ICON6): a randomised, double-blind, placebo-controlled phase 3 trial

    Jonathan A Ledermann;Andrew C Embleton;Fharat Raja;Timothy J Perren

  • Neoadjuvant chemotherapy versus debulking surgery in advanced tubo-ovarian cancers: pooled analysis of individual patient data from the EORTC 55971 and CHORUS trials.

    I Vergote;C Coens;M Nankivell;G B Kristensen

  • Randomized Phase II Placebo-Controlled Trial of Maintenance Therapy Using the Oral Triple Angiokinase Inhibitor BIBF 1120 After Chemotherapy for Relapsed Ovarian Cancer

    Jonathan A Ledermann;Allan Hackshaw;Stan B Kaye;Gordon C Jayson

  • Blockade of Platelet-Derived Growth Factor Receptor-Beta by CDP860, a Humanized, PEGylated di-Fab', Leads to Fluid Accumulation and Is Associated With Increased Tumor Vascularized Volume

    Gordon C Jayson;Geoff J M Parker;Saifee A Mullamitha;Juan W Valle

Frequent Co-Authors

Alan Jackson
Alan Jackson Arizona State University
Geoff J.M. Parker
Geoff J.M. Parker University College London
Caroline Dive
Caroline Dive University of Manchester
Jonathan A. Ledermann
Jonathan A. Ledermann University College London
Juan W. Valle
Juan W. Valle University of Manchester
Chris Todd
Chris Todd University of Manchester
John T. Gallagher
John T. Gallagher University of Manchester
Henry C Kitchener
Henry C Kitchener University of Manchester
Stan B. Kaye
Stan B. Kaye Royal Marsden NHS Foundation Trust
Fiona H Blackhall
Fiona H Blackhall University of Manchester

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

For students interested in Medicine, there are numerous online degree options offering flexible pathways into healthcare careers. The demand for qualified nurses and advanced practitioners continues to rise, encouraging many to explore affordable programs designed for working adults.

If you’re considering becoming a nurse practitioner, several cheapest np school options offer accredited, high-quality education without a heavy financial burden. For those starting their nursing journey, it’s worth exploring the cheapest bsn programs online for a cost-effective entry into the field.

Advancing your nursing practice with a doctorate is also more accessible with the cheapest dnp programs online, helping you reach leadership or specialist roles. If you already hold an RN and want to advance your qualifications, check out the most affordable accredited online rn to bsn programs.

These options empower future healthcare professionals to grow their careers, increase earning potential, and contribute meaningfully to the health sector, all while managing tuition costs.

Best Scientists Citing Gordon C Jayson

Trending Scientists

Recently Published Articles